DCM
KNTE

Dupont Capital Management’s Kinnate Biopharma Inc. Common Stock KNTE Stock Holding History

Dupont Capital Management’s Portfolio KNTE Stock Details KNTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-8,804
Closed -$156K – 1811
2021
Q4 		$156K Sell
8,804
-3,511
-29% -$74K 0.01% 1198
2021
Q3 		$283K Buy
+12,315
New +$268K 0.01% 1098

Other funds holding KNTE

FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Dupont Capital Management's KNTE Position: Q1 2022 in Review

Dupont Capital Management sold out of Kinnate Biopharma Inc. Common Stock (KNTE) in Q1 2022, closing a stake of 8,804 shares — an estimated $156K sold.

Dupont Capital Management first reported a position in KNTE in Q3 2021 and held it in 2 quarters. The position peaked at $283K in Q3 2021. 76 funds tracked by Wall St. Rank hold KNTE as of Q1 2022.

  • Dupont Capital Management reported no remaining Kinnate Biopharma Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Dupont Capital Management sold 8,804 Kinnate Biopharma Inc. Common Stock shares in Q1 2022, an estimated $156K.
  • Dupont Capital Management first reported a position in Kinnate Biopharma Inc. Common Stock in Q3 2021 and held it in 2 quarters.
  • Dupont Capital Management's Kinnate Biopharma Inc. Common Stock position peaked at $283K in Q3 2021.
  • 76 funds tracked by Wall St. Rank held Kinnate Biopharma Inc. Common Stock as of Q1 2022.

Based on Dupont Capital Management's 13F filing for Q1 2022, filed 27 Apr 2022.